Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Allergan's Restasis (cyclosporine) ophthalmic emulsion, 0.05% w/v received approval from Health Canada for the treatment of moderate to moderately severe Dry Eye disease (Dry Eye).
Subscribe to our email newsletter
Allergan said that Restasis is the first prescription eye drop to target the underlying cause of chronic Dry Eye.
Allergan claimed that Restasis helps increase the eye’s natural ability to produce tears, which may be reduced by inflammation due to Dry Eye.
University of Ottawa Eye Institute, The Ottawa Hospital Ophthalmology professor Bruce Jackson said that by increasing tear production, Restasis is the first approved drug that targets the underlying cause of Dry Eye.